From One Child to Many: The Quest to Scale Bespoke Genetic Therapies

Julia Vitarello, a mother who famously championed a one-of-a-kind treatment for her daughter Mila's rare genetic mutation, has announced she is launching a new biotechnology venture. This initiative aims to produce such individualized therapies on a larger scale, moving beyond the single-patient model that saved her daughter's life.

Mila's Story: The Birth of a Personalized Medicine

Eight years ago, Julia Vitarello’s daughter Mila was diagnosed with a devastating neurological condition caused by a unique mutation in the CLN7 gene. No existing drug could target that specific error. In an unprecedented move, researchers designed a custom antisense oligonucleotide — a bespoke genetic therapy — tailored precisely to Mila's mutation. The treatment, often called "Mila's miracle," halted the disease's progression and gave her years of improved quality of life.

A Unique Mutation, a Custom Drug

Mila’s case became a landmark example of N-of-1 medicine — a therapy designed for a single patient. The approach required coordinated efforts from academic scientists, the FDA, and philanthropists. Vitarello’s relentless advocacy helped pave the way for this personalized approach, inspiring many families with similarly rare conditions.

The EveryONE Medicines Experience

Following Mila's success, Vitarello founded EveryONE Medicines, a company dedicated to developing customized therapies for multiple patients with ultra-rare mutations. The goal was to streamline the process so that many families could benefit from the same kind of bespoke treatment.

Challenges with FDA Guidance and Investor Confidence

Despite early promise, EveryONE Medicines recently ceased operations. According to Vitarello, the principal hurdle was the U.S. Food and Drug Administration's guidance on customized therapies. While the FDA encouraged development of such treatments, the agency did not provide a clear enough regulatory pathway to satisfy EveryONE's investors. Vitarello explained that investors need predictable frameworks to justify the high costs and risks of manufacturing individualized medicines. The lack of defined approval routes made it difficult to secure ongoing funding.

Other challenges included:

• High development costs for each unique therapy
• Regulatory uncertainty on how to approve one-off drugs
• Manufacturing scalability — making dozens of different custom molecules efficiently
• Reimbursement questions from insurers

A New Biotech: Scaling Up Individualized Therapies

Now Vitarello is in the process of establishing a new biotech company. She and her collaborators are actively seeking fresh funding to build a platform that can produce bespoke genetic therapies at scale. The goal is to move beyond the one-off model toward a system that can treat multiple patients, each with their own custom drug, without starting from scratch every time.

The Vision for the Future

Vitarello envisions a future where a patient’s genetic information can be rapidly analyzed, a custom therapy designed within weeks, and manufacturing streamlined to serve many individuals simultaneously. The new company intends to leverage advances in RNA technology and automated synthesis to lower costs and turnaround times. She hopes to attract investors who share a long-term vision and are willing to engage with regulators to establish clearer guidelines.

Key elements of the new venture include:

1. Platform technology that can design therapies for multiple mutations quickly
2. Collaborative networks with academic researchers and clinical centers
3. Proactive engagement with the FDA to create workable regulatory pathways
4. Sustainable funding models that reduce reliance on single-source philanthropists

While EveryONE Medicines is no longer active, Vitarello remains determined. "We cannot let Mila’s story be an exception," she said. "It must become the rule."

The rise of customized gene modulation treatments could transform the landscape for thousands of families affected by ultra-rare diseases — conditions that previously had no treatment options. Vitarello’s new effort represents a bold step toward making N-of-1 therapies not just possible, but predictable and accessible.